Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the anti-proliferative and cytotoxic effects of CCT137690 on estrogen receptor (ER)-positive human breast cancer cell line (MCF-7) and ER-negative human breast cancer cell line (MDA-MB-231).
|
31319040 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The resistance to the endocrine therapy of breast cancer leads to the emergence of new class of drugs that downregulates the estrogen receptor action known as selective estrogen receptor downregulators (SERDs).
|
31038398 |
2020 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Alcohol intake was positively associated with overall BC risk and specifically with estrogen receptor-positive tumors with respectively TE = 1.17(95%CI: 1.01,1.35) and 1.36(1.08,1.70) for a 1-standard deviation (1-SD) increase of intake.
|
30968961 |
2020 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The expression of carbonic anhydrase XII (CA12) is associated with the expression of estrogen receptor alpha (ERα) in breast cancer and is linked to a good prognosis with a lower risk of metastasis.
|
31636386 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this paper, we present a prospective observational study, which determines the incidence of bone metastases and its correlation with hormonal receptors (estrogen receptor [ER]/progesterone receptor [PR]) and human epidermal growth factor receptor 2 (HER2) in breast cancer.
|
31603096 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
A great hallmark of breast cancer is the absence or presence of estrogen receptors ERα and ERβ, with a dominant role in cell proliferation, differentiation and cancer progression.
|
31401293 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
|
31559573 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Using an unbiased cell line screening approach, we tested the sensitivity of breast cancer cell lines to taselisib, a potent PI3K inhibitor, and correlated sensitivity with key biomarkers (PIK3CA, HER2, PTEN, ESR1).
|
31534012 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The cure rate of patients with ERα-positive breast cancer is, however, limited due to the occurrence of endocrine resistance.
|
31701491 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Prospective cohort studies of Cd and breast cancer risk suggest a significant relationship between increased Cd intake and cancer incidence, with more pronounced effects for estrogen receptor α (ERα)-positive breast cancers.
|
31689473 |
2020 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
rs2234693 and rs9340799 polymorphisms in the ESR1 gene were not associated with susceptibility for BC.
|
31786857 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
This focused review highlights recent achievements in pre-clinical and clinical imaging of ER and PR in breast cancer.
|
31732674 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
In general, associations of risk factors for ER+ DCIS were similar in magnitude and direction to those for invasive ER+ breast cancer.
|
31786415 |
2020 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay.
|
31385051 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The risk of SPM was significantly related to the following demographical and clinical variables: age (40-59 vs. 18-39, HR = 1.33; 60-79 vs. 18-39, HR = 2.39; ≥80 vs. 18-39, HR = 2.84), race (black vs. white, HR = 1.12), histological type (lobular BC vs. ductal BC, HR = 1.15), radiotherapy (HR = 1.33), marital status (married vs. single, HR = 0.88) and estrogen receptor status (positive vs. negative, HR = 0.85).
|
30861567 |
2020 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
|
31734822 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) are the three crucial biomarkers for the clinical diagnosis of breast cancer.
|
31665670 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
The absence of ER in breast cancer before and after NAC would be a significant prognostic factor for local recurrence and distant metastasis.
|
31204155 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
In the present study, we investigated the effects of lupiwighteone on the proliferation and apoptosis of two different human cancer cells; MCF-7, an estrogen receptor (ER)-positive human breast cancer cell, and MDA-MB-231, a triple negative human breast cancer cell.
|
31604113 |
2020 |
Malignant neoplasm of breast
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
The AP-2γ transcription factor, encoded by the <i>TFAP2C</i> gene, regulates the expression of estrogen receptor-alpha (ERα) and other genes associated with hormone response in luminal breast cancer.
|
31619506 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
This study underlines the importance of the EGFR ligand, Amphiregulin, as a key mediator of estrogen receptor action in breast cancer.
|
31838731 |
2020 |
Malignant neoplasm of breast
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ligand-binding domain (LBD) of the ESR1 gene result in resistance to estrogen deprivation therapy (EDT) in breast cancer.
|
31669227 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, due to the overexpression of the estrogen receptor (ER) in breast cancer and the ability of ER to specifically bind to its ligand estrone (ES), an ES-targeted PEGylated epirubicin (EPI) and paclitaxel (PTX) co-loaded liposomal nanoparticle (NP) (termed as ES-SSL-EPI/PTX) was developed.
|
31678519 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Ax-pCR was more likely to be achieved in patients who were diagnosed with ER-negative and high-grade breast cancer and those with ycN0 and clinical CR at the primary site after NAC than among others.
|
31367884 |
2020 |
Malignant neoplasm of breast
|
1.000 |
Biomarker
|
disease |
BEFREE |
Endocrine therapy resistance in breast cancer is a major obstacle in the treatment of patients with estrogen receptor-positive (ER+) tumors.
|
31595691 |
2020 |